Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972123 · ClinicalTrials.gov registry record · Phase 2
The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT04972123 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 143 participants.
The verdict
NCT04972123, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
Syncope is defined as transient loss of consciousness associated with inability to maintain postural tone with rapid and spontaneous recovery. The purpose of this study is to assess the effects of sublingual administration of a new medication called CPC on tilt-induced syncope in patients with a history of vasovagal syncope (VVS) or near syncope. 140 participants will be randomized at the University of Wisconsin - Madison. Each participant will be in the study for 1 day.
Interventions
- DRUG Placebo
- DRUG CPC - Capsaicin, Phenylephrine, Caffeine
- DIAGNOSTIC_TEST Tilt Table Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2021-07-20 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04972123
The ClinicalTrials.gov registry entry for NCT04972123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04972123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04972123 about?
NCT04972123 is a clinical study titled "The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope". Syncope is defined as transient loss of consciousness associated with inability to maintain postural tone with rapid and spontaneous recovery. The purpose of this study is to assess the effects of sublingual administration of a new medication called CPC on tilt-induced syncope in patients with a his...
What is the current status of trial NCT04972123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2021-07-20. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04972123?
The interventions under investigation include: Placebo (DRUG), CPC - Capsaicin, Phenylephrine, Caffeine (DRUG), Tilt Table Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04972123?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.